Financial Data and Key Metrics Changes - For the full year 2025, the company generated revenue of $120.5 million, representing nearly 9% year-over-year growth [7] - In Q4 2025, revenue reached $34.4 million, up nearly 22% year-over-year, indicating accelerating momentum [7] - GAAP net income for 2025 was $10.8 million, a year-over-year increase of more than 37%, with earnings per share of $0.10 [7] - Adjusted EBITDA expanded to $27.5 million with a 23% margin, up more than 14% year-over-year [8] - Free cash flow for 2025 reached approximately $20.5 million, compared to $13.2 million in 2024, representing growth of more than 500% from 2023 [8] Business Line Data and Key Metrics Changes - The company completed multiple acquisitions in 2025, including Medsphere Systems, which expanded its capabilities into the inpatient hospital market [10] - The integration of AI tools into the platform has already resulted in new customer wins under the CareCloud umbrella [11] - The company aims to penetrate newly acquired health system customers with its RCM and AI products as part of its 2026 growth strategy [12] Market Data and Key Metrics Changes - The healthcare technology market is at an inflection point, with AI adoption moving from pilot programs to production deployment [12] - The company recognizes a multi-billion-dollar addressable opportunity in the U.S. for its AI front desk assistant [12] Company Strategy and Development Direction - The company’s 2026 growth strategy focuses on leveraging its dual platform footprint in ambulatory and inpatient markets to drive organic growth and acquisition synergies [13] - Strategic acquisitions have been a cornerstone of growth, with a disciplined approach to acquiring companies at attractive valuations [14] - The company plans to remain active in M&A in 2026 and beyond, identifying complementary targets that can benefit from its AI capabilities [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance of $128 million to $130 million for 2026, with adjusted EBITDA of $29 million to $31 million [15] - The company anticipates GAAP EPS of $0.20 to $0.23 per share, representing an increase of more than 100% over 2025 [15] - Management highlighted the importance of disciplined execution, innovation, and creating long-term value for stakeholders [35] Other Important Information - The company resumed dividends on its preferred shares at the beginning of 2025 and plans to pay double dividends on Series B preferred stock starting in 2026 [9] - The conversion of approximately 80% of Series A preferred shares into common eliminated more than $7 million in annual dividend obligations [9] Q&A Session Summary Question: Can you expand on how you're planning on monetizing AI in 2026? - Management discussed the favorable M&A environment and the strategy to integrate AI capabilities into acquired platforms, enhancing their attractiveness and market position [38][41] Question: What was behind the recent contract wins with new customers? - Management noted the expansion of the sales and marketing team and the focus on cross-selling and upselling existing customers, particularly those acquired through recent transactions [45][46] Question: How should investors think about CareCloud's exposure to AI disruption? - Management emphasized that the company operates in a niche healthcare IT space with deep industry moats, making it less vulnerable to generic AI disruptions [54][56] Question: What are the focuses for the use of excess cash flow? - Management indicated that the focus would be on acquisitions, enhancing the capital structure, and investing in AI development [73] Question: Who are the company's main competitors? - Management identified competitors in the EHR space such as eClinicalWorks and athenahealth, and noted that the AI competitive landscape is broader, with some players lacking a vertical approach [75][78]

Financial Data and Key Metrics Changes - For the full year 2025, the company generated revenue of $120.5 million, representing nearly 9% year-over-year growth [7] - In Q4 2025, revenue reached $34.4 million, up nearly 22% year-over-year, indicating accelerating momentum [7] - GAAP net income for 2025 was $10.8 million, a year-over-year increase of more than 37%, with earnings per share of $0.10 [7] - Adjusted EBITDA expanded to $27.5 million with a 23% margin, up more than 14% year-over-year [8] - Free cash flow reached approximately $20.5 million for 2025, compared to $13.2 million in 2024, representing growth of more than 500% from 2023 [8] Business Line Data and Key Metrics Changes - The company completed multiple acquisitions in 2025, including Medsphere Systems, which expanded its capabilities into the inpatient hospital market [10] - The integration of AI tools into the platform has already resulted in new customer wins under the CareCloud umbrella [11] - The company aims to penetrate newly acquired health system customers with its RCM and AI products as part of its 2026 growth strategy [12] Market Data and Key Metrics Changes - The healthcare technology market is at an inflection point, with AI adoption moving from pilot programs to production deployment [12] - The company recognizes a multi-billion-dollar addressable opportunity in the U.S. for its AI front desk assistant [12] Company Strategy and Development Direction - The company’s 2026 growth strategy focuses on leveraging its dual platform footprint in ambulatory and inpatient markets to drive organic growth and acquisition synergies [13] - Strategic acquisitions have been a cornerstone of growth, with a disciplined approach to acquiring companies at attractive valuations [14] - The company plans to remain active in M&A in 2026 and beyond, identifying complementary targets that can benefit from its AI capabilities [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance of $128 million-$130 million for 2026, with adjusted EBITDA of $29 million-$31 million [15] - The company anticipates GAAP EPS of $0.20-$0.23 per share, representing an increase of more than 100% over 2025 [15] - Management highlighted the importance of disciplined execution and innovation to create long-term value for stakeholders [35] Other Important Information - The company resumed dividends on its preferred shares at the beginning of 2025 and plans to pay double dividends on Series B preferred stock starting in 2026 [9] - The conversion of approximately 80% of Series A preferred shares into common eliminated more than $7 million in annual dividend obligations [9] Q&A Session Summary Question: Can you expand on how you're planning on monetizing AI in 2026? - Management discussed the favorable M&A environment and the strategy to integrate AI capabilities into acquired platforms to enhance their attractiveness and market position [38][41] Question: What was behind the recent contract wins and future opportunities? - Management noted the expansion of the sales team and the focus on cross-selling additional services to existing clients acquired through recent transactions [45][46] Question: How does CareCloud's exposure to AI disruption compare to being an AI beneficiary? - Management emphasized that CareCloud operates in a niche healthcare IT space with deep industry moats, making it less vulnerable to generic AI disruptions [54][56] Question: What are the focuses for the use of excess cash flow? - Management indicated that the focus would be on acquisitions, enhancing capital structure, and investing in AI development [73] Question: Who are CareCloud's main competitors? - Management identified competitors in the EHR space such as eClinicalWorks and athenahealth, and noted that the AI competitive landscape varies depending on the product [75][76]

Financial Data and Key Metrics Changes - For the full year 2025, the company generated revenue of $120.5 million, representing nearly 9% year-over-year growth, with Q4 revenue of $34.4 million, up nearly 22% year-over-year [6][32] - GAAP net income for 2025 was $10.8 million, a year-over-year increase of more than 37%, with earnings per share of $0.10, marking the first full year of positive EPS since the 2014 IPO [6][31] - Adjusted EBITDA expanded to $27.5 million with a 23% margin, up more than 14% year-over-year [7][33] - Free cash flow reached approximately $20.5 million for 2025, compared to $13.2 million in 2024, representing growth of more than 500% from 2023 [7][34] Business Line Data and Key Metrics Changes - The company completed multiple acquisitions in 2025, including Medsphere Systems, which expanded its capabilities into the inpatient hospital market [9][10] - Revenue related to the Medsphere acquisition in Q4 was approximately $7.2 million [32] Market Data and Key Metrics Changes - The healthcare technology market is at an inflection point, with AI adoption moving from pilot programs to production deployment, creating a multi-billion-dollar addressable opportunity in the U.S. [11][12] - The company aims to leverage its dual platform footprint in ambulatory and inpatient markets to drive organic growth and acquisition synergies [12] Company Strategy and Development Direction - The 2026 growth strategy focuses on penetrating newly acquired health system customers with RCM and AI products, emphasizing operating leverage from strategic investments [11][14] - The company plans to remain active in M&A in 2026 and beyond, identifying complementary targets that can benefit from its AI capabilities [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance of $128 million-$130 million for 2026, with adjusted EBITDA of $29 million-$31 million and GAAP EPS of $0.20-$0.23 per share, representing over 100% growth from 2025 [14][15] - The company highlighted its strong financial position, with zero drawn on its credit line and a focus on disciplined execution and innovation [15][34] Other Important Information - The company resumed dividends on preferred shares in early 2025 and began paying double dividends on Series B preferred stock starting in 2026 [8][31] - The AI Center of Excellence was launched in April 2025, focusing on building AI solutions that create measurable impact for healthcare providers [17][18] Q&A Session Summary Question: Can you expand on how you're planning on monetizing AI in 2026? - Management discussed the favorable M&A environment and the strategy to integrate AI capabilities into acquired platforms, enhancing their attractiveness and market position [39][41] Question: What was behind the recent contract wins and future opportunities? - The company has expanded its sales and marketing team, focusing on cross-selling and upselling to existing customers acquired through recent transactions [45][46] Question: How should investors think about CareCloud's exposure to AI disruption? - Management emphasized that CareCloud operates in a niche healthcare IT market with deep industry moats, making it less vulnerable to generic AI disruptions [54][55] Question: What are the focuses for the use of excess cash flow? - The company aims to use excess cash flow for acquisitions, enhancing capital structure, and investing in AI development [73][74] Question: Who are CareCloud's main competitors? - Competitors include eClinicalWorks, AdvancedMD, and athenahealth in the EHR space, with a wider field in AI solutions [75][76]

© CareCloud, Inc. 2025 DRIVING NEXT-GEN HEALTHCARE WITH GENERATIVE AI SOLUTIONS Nasdaq Global Market: CCLD, CCLDO Investor Presentation May 2025 A healthcare technology company with 25 years of experience, delivering AI-driven, end-to-end solutions that power real- world clinical and financial transformation. Safe Harbor Statements This presentation contains forward-looking statements within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of o ...

Core Insights - CareCloud has been named Maxim Group's "Top Healthcare IT Pick for 2025" due to its transformative AI strategy and strong financial performance [1][2][3] - The company is trading at a 2026 EV/EBITDA multiple of 5.0x, significantly lower than the peer group average of 12.5x, indicating an attractive investment opportunity [2] - CareCloud's Q1 2025 performance showed a 52% year-over-year growth in adjusted EBITDA, highlighting its operational momentum [4] Company Strategy and Developments - CareCloud's AI Center of Excellence was launched with an initial team of over 50 AI professionals, aiming to scale to 500 by year-end, positioning the company as a leader in applied AI within healthcare [4] - The company emphasizes that AI is integrated into its core operations, enhancing documentation, revenue cycle management, patient engagement, and analytics [5] - CareCloud's AI suite, including tools like cirrusAI Notes, cirrusAI Appeals, and cirrusAI Voice, is highlighted as a key differentiator in the market [3] Financial Performance - The company has resumed preferred dividends and is returning to M&A-driven growth, contributing to its positive outlook [3] - CareCloud's commitment to delivering cost-effective technology aims to improve healthcare outcomes and operational efficiency for its clients [5] - More than 40,000 providers rely on CareCloud's solutions to enhance patient care while reducing administrative burdens [6]

Financial Data and Key Metrics Changes - Free cash flow reached record levels of $13.2 million, a year-over-year increase of nearly 250% [11] - Adjusted EBITDA rose to $24.1 million, a 56% increase year-over-year [11] - Net income surged to an all-time high of $7.9 million, compared to a net loss of $48.7 million in 2023 [39][43] - Revenue for Q4 2024 was $28.2 million, slightly down from $28.4 million in Q4 2023 [40] - GAAP net income for Q4 2024 was $3.3 million, compared to a net loss of $43.7 million in the same period last year [39] Business Line Data and Key Metrics Changes - Recurring technology-enabled business solution revenues were $24.8 million, essentially flat with Q4 2023 [40] - Non-recurring professional services revenues from medSR declined by approximately $400,000 [40] Market Data and Key Metrics Changes - The company anticipates revenue growth in the range of $111 million to $114 million for 2025, indicating a shift towards positive growth after previous declines [17] - Adjusted EBITDA for 2025 is projected to be between $26 million and $28 million [17] Company Strategy and Development Direction - The conversion of Series A preferred shares into common stock was a significant strategic move, aimed at optimizing the capital structure and enhancing shareholder value [13][15] - The company is focused on leveraging AI-driven solutions to improve provider efficiency and reduce administrative burdens [19] - CareCloud plans to expand specialty-based EHR solutions, targeting distinct needs of various medical specialties [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive earnings per share for the first time since going public in 2014, reflecting the strength of the business transformation [11][18] - The company remains focused on strategic growth, efficiency, and expansion, with a commitment to innovation [17][35] Other Important Information - The company has fully repaid its Silicon Valley Bank line of credit and is now bank debt-free [38] - The removal of dividend obligations tied to preferred shares will free up additional resources for reinvestment into key growth areas [16] Q&A Session Summary Question: Revenue and EBITDA guidance for the year - Management indicated that they expect revenue growth in 2025, with a range of $111 million to $114 million, and adjusted EBITDA between $26 million and $28 million, reflecting a disciplined approach to cost management and innovation [54][55] Question: Insights on M&A pipeline and valuations - Management confirmed a re-entry into the acquisition market, focusing on smaller and mid-sized medical billing companies, with a disciplined approach to ensure any deals pursued are accretive and align with long-term objectives [60][64] Question: User base expansion and offerings - The user base is diversified, with a significant portion in primary care, and management sees opportunities to upsell various solutions to existing clients [70][72] Question: 2025 guidance and customer attrition - The 2025 revenue guidance does not factor in any material acquisitions, focusing instead on organic growth and small tuck-in opportunities [77][78] Question: Preferred stocks and dividends - Management clarified the Series A conversion details and ongoing obligations for the remaining preferred shares, indicating that dividends will continue to be paid on the outstanding shares [96][98]